Home > > > > Report Detail

Global Varicella Attenuated Live Vaccine Market Research Report 2024

Publisher Name :
Date: 08-Jan-2024
No. of pages: 80
Inquire Before Buying

A live attenuated varicella vaccine, derived from The Oka strain of VZV has clinical efficacy for The prevention of varicella.

The global Varicella Attenuated Live Vaccine market was valued at US$ 2553.6 million in 2023 and is anticipated to reach US$ 3440.8 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030.

For The major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in The ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of The Global Varicella Attenuated Live Vaccine revenue market share in 2019.

The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied The largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.

This report aims to provide a comprehensive presentation of The global market for Varicella Attenuated Live Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess The market competitive situation, analyze their position in The current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccine.

Report Scope

The Varicella Attenuated Live Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as The base year, with history and forecast data for The period from 2019 to 2030. This report segments The global Varicella Attenuated Live Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of The market, The report provides profiles of The competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help The Varicella Attenuated Live Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on The revenues, sales volume, and average price for The overall market and The sub-segments across The different segments, By Company, by Type, by Application, and By Regions.

Market Segmentation

By Company

- Merck

- BCHT

- Shanghai Institute

- GSK

- Keygen

- Green Cross

- Biken

- Shanghai Rongsheng Biotech

- Changchun Changsheng Life Sciences Limited

Segment by Type

- Monovalent Vaccine

- Combination Vaccine

Segment by Application

- Kids Injection

- Adults Injection

Consumption By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

Chapter Outline

Chapter 1: Introduces The Report Scope of The report, executive summary of different market segments (

By Region, by Type, by Application, etc), including The market size of each market segment, future development potential, and so on. It offers a high-level view of The current state of The market and its likely evolution in The short to mid-term, and long term.

Chapter 2: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Varicella Attenuated Live Vaccine in regional level and country level. It provides a quantitative analysis of The market size and development potential of each region and its main countries and introduces The market development, future development prospects, market space, and market size of each country in The world.

Chapter 4: Provides The analysis of various market segments by Type, covering The market size and development potential of each market segment, to help readers find The blue ocean market in different market segments.

Chapter 5: Provides The analysis of various market segments by Application, covering The market size and development potential of each market segment, to help readers find The blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing The basic situation of The main companies in The market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including The upstream and downstream of The industry.

Chapter 8: Introduces The market dynamics, latest developments of The market, The driving factors and restrictive factors of The market, The challenges and risks faced by manufacturers in The industry, and The analysis of relevant policies in The industry.

Chapter 9: The main points and conclusions of The report.

Global Varicella Attenuated Live Vaccine Market Research Report 2024

Table of Contents
1 Varicella Attenuated Live Vaccine Market Overview
1.1 Product Overview and Scope of Varicella Attenuated Live Vaccine
1.2 Varicella Attenuated Live Vaccine Segment by Type
1.2.1 Global Varicella Attenuated Live Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Varicella Attenuated Live Vaccine Segment by Application
1.3.1 Global Varicella Attenuated Live Vaccine Market Value by Application: (2024-2030)
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Global Varicella Attenuated Live Vaccine Market Size Estimates and Forecasts
1.4.1 Global Varicella Attenuated Live Vaccine Revenue 2019-2030
1.4.2 Global Varicella Attenuated Live Vaccine Sales 2019-2030
1.4.3 Global Varicella Attenuated Live Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Varicella Attenuated Live Vaccine Market Competition by Manufacturers
2.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Varicella Attenuated Live Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Varicella Attenuated Live Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Product Type & Application
2.7 Varicella Attenuated Live Vaccine Market Competitive Situation and Trends
2.7.1 Varicella Attenuated Live Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Varicella Attenuated Live Vaccine Players Market Share by Revenue
2.7.3 Global Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Varicella Attenuated Live Vaccine Retrospective Market Scenario by Region
3.1 Global Varicella Attenuated Live Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Varicella Attenuated Live Vaccine Global Varicella Attenuated Live Vaccine Sales by Region: 2019-2030
3.2.1 Global Varicella Attenuated Live Vaccine Sales by Region: 2019-2024
3.2.2 Global Varicella Attenuated Live Vaccine Sales by Region: 2025-2030
3.3 Global Varicella Attenuated Live Vaccine Global Varicella Attenuated Live Vaccine Revenue by Region: 2019-2030
3.3.1 Global Varicella Attenuated Live Vaccine Revenue by Region: 2019-2024
3.3.2 Global Varicella Attenuated Live Vaccine Revenue by Region: 2025-2030
3.4 North America Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.4.1 North America Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.4.3 North America Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.5.1 Europe Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.5.3 Europe Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.7.1 Latin America Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Varicella Attenuated Live Vaccine Sales by Type (2019-2030)
4.1.1 Global Varicella Attenuated Live Vaccine Sales by Type (2019-2024)
4.1.2 Global Varicella Attenuated Live Vaccine Sales by Type (2025-2030)
4.1.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2019-2030)
4.2.1 Global Varicella Attenuated Live Vaccine Revenue by Type (2019-2024)
4.2.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2025-2030)
4.2.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Varicella Attenuated Live Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Varicella Attenuated Live Vaccine Sales by Application (2019-2030)
5.1.1 Global Varicella Attenuated Live Vaccine Sales by Application (2019-2024)
5.1.2 Global Varicella Attenuated Live Vaccine Sales by Application (2025-2030)
5.1.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2019-2030)
5.2.1 Global Varicella Attenuated Live Vaccine Revenue by Application (2019-2024)
5.2.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2025-2030)
5.2.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Varicella Attenuated Live Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Varicella Attenuated Live Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 BCHT
6.2.1 BCHT Corporation Information
6.2.2 BCHT Description and Business Overview
6.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 BCHT Varicella Attenuated Live Vaccine Product Portfolio
6.2.5 BCHT Recent Developments/Updates
6.3 Shanghai Institute
6.3.1 Shanghai Institute Corporation Information
6.3.2 Shanghai Institute Description and Business Overview
6.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio
6.3.5 Shanghai Institute Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK Varicella Attenuated Live Vaccine Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Keygen
6.5.1 Keygen Corporation Information
6.5.2 Keygen Description and Business Overview
6.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Keygen Varicella Attenuated Live Vaccine Product Portfolio
6.5.5 Keygen Recent Developments/Updates
6.6 Green Cross
6.6.1 Green Cross Corporation Information
6.6.2 Green Cross Description and Business Overview
6.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Green Cross Varicella Attenuated Live Vaccine Product Portfolio
6.6.5 Green Cross Recent Developments/Updates
6.7 Biken
6.6.1 Biken Corporation Information
6.6.2 Biken Description and Business Overview
6.6.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biken Varicella Attenuated Live Vaccine Product Portfolio
6.7.5 Biken Recent Developments/Updates
6.8 Shanghai Rongsheng Biotech
6.8.1 Shanghai Rongsheng Biotech Corporation Information
6.8.2 Shanghai Rongsheng Biotech Description and Business Overview
6.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio
6.8.5 Shanghai Rongsheng Biotech Recent Developments/Updates
6.9 Changchun Changsheng Life Sciences Limited
6.9.1 Changchun Changsheng Life Sciences Limited Corporation Information
6.9.2 Changchun Changsheng Life Sciences Limited Description and Business Overview
6.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio
6.9.5 Changchun Changsheng Life Sciences Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Varicella Attenuated Live Vaccine Industry Chain Analysis
7.2 Varicella Attenuated Live Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Varicella Attenuated Live Vaccine Production Mode & Process
7.4 Varicella Attenuated Live Vaccine Sales and Marketing
7.4.1 Varicella Attenuated Live Vaccine Sales Channels
7.4.2 Varicella Attenuated Live Vaccine Distributors
7.5 Varicella Attenuated Live Vaccine Customers
8 Varicella Attenuated Live Vaccine Market Dynamics
8.1 Varicella Attenuated Live Vaccine Industry Trends
8.2 Varicella Attenuated Live Vaccine Market Drivers
8.3 Varicella Attenuated Live Vaccine Market Challenges
8.4 Varicella Attenuated Live Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Varicella Attenuated Live Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Varicella Attenuated Live Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Varicella Attenuated Live Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Varicella Attenuated Live Vaccine Sales (K Doses) of Key Manufacturers (2019-2024)
Table 5. Global Varicella Attenuated Live Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Varicella Attenuated Live Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Varicella Attenuated Live Vaccine Average Price (USD/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Varicella Attenuated Live Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Varicella Attenuated Live Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Varicella Attenuated Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Varicella Attenuated Live Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Varicella Attenuated Live Vaccine Sales by Region (2019-2024) & (K Doses)
Table 18. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Varicella Attenuated Live Vaccine Sales by Region (2025-2030) & (K Doses)
Table 20. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Varicella Attenuated Live Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Varicella Attenuated Live Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Varicella Attenuated Live Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Varicella Attenuated Live Vaccine Sales by Country (2019-2024) & (K Doses)
Table 27. North America Varicella Attenuated Live Vaccine Sales by Country (2025-2030) & (K Doses)
Table 28. North America Varicella Attenuated Live Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Varicella Attenuated Live Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Varicella Attenuated Live Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Varicella Attenuated Live Vaccine Sales by Country (2019-2024) & (K Doses)
Table 32. Europe Varicella Attenuated Live Vaccine Sales by Country (2025-2030) & (K Doses)
Table 33. Europe Varicella Attenuated Live Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Varicella Attenuated Live Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Varicella Attenuated Live Vaccine Sales by Region (2019-2024) & (K Doses)
Table 37. Asia Pacific Varicella Attenuated Live Vaccine Sales by Region (2025-2030) & (K Doses)
Table 38. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Varicella Attenuated Live Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Varicella Attenuated Live Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Varicella Attenuated Live Vaccine Sales by Country (2019-2024) & (K Doses)
Table 42. Latin America Varicella Attenuated Live Vaccine Sales by Country (2025-2030) & (K Doses)
Table 43. Latin America Varicella Attenuated Live Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Varicella Attenuated Live Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Varicella Attenuated Live Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Country (2019-2024) & (K Doses)
Table 47. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Country (2025-2030) & (K Doses)
Table 48. Middle East & Africa Varicella Attenuated Live Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Varicella Attenuated Live Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Type (2019-2024)
Table 51. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Type (2025-2030)
Table 52. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Type (2019-2024)
Table 59. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Type (2025-2030)
Table 60. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Application (2019-2024)
Table 61. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Application (2025-2030)
Table 62. Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Application (2019-2024)
Table 69. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Application (2025-2030)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 73. Merck Varicella Attenuated Live Vaccine Product
Table 74. Merck Recent Developments/Updates
Table 75. BCHT Corporation Information
Table 76. BCHT Description and Business Overview
Table 77. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 78. BCHT Varicella Attenuated Live Vaccine Product
Table 79. BCHT Recent Developments/Updates
Table 80. Shanghai Institute Corporation Information
Table 81. Shanghai Institute Description and Business Overview
Table 82. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 83. Shanghai Institute Varicella Attenuated Live Vaccine Product
Table 84. Shanghai Institute Recent Developments/Updates
Table 85. GSK Corporation Information
Table 86. GSK Description and Business Overview
Table 87. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 88. GSK Varicella Attenuated Live Vaccine Product
Table 89. GSK Recent Developments/Updates
Table 90. Keygen Corporation Information
Table 91. Keygen Description and Business Overview
Table 92. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 93. Keygen Varicella Attenuated Live Vaccine Product
Table 94. Keygen Recent Developments/Updates
Table 95. Green Cross Corporation Information
Table 96. Green Cross Description and Business Overview
Table 97. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 98. Green Cross Varicella Attenuated Live Vaccine Product
Table 99. Green Cross Recent Developments/Updates
Table 100. Biken Corporation Information
Table 101. Biken Description and Business Overview
Table 102. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 103. Biken Varicella Attenuated Live Vaccine Product
Table 104. Biken Recent Developments/Updates
Table 105. Shanghai Rongsheng Biotech Corporation Information
Table 106. Shanghai Rongsheng Biotech Description and Business Overview
Table 107. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 108. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product
Table 109. Shanghai Rongsheng Biotech Recent Developments/Updates
Table 110. Changchun Changsheng Life Sciences Limited Corporation Information
Table 111. Changchun Changsheng Life Sciences Limited Description and Business Overview
Table 112. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 113. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product
Table 114. Changchun Changsheng Life Sciences Limited Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Varicella Attenuated Live Vaccine Distributors List
Table 118. Varicella Attenuated Live Vaccine Customers List
Table 119. Varicella Attenuated Live Vaccine Market Trends
Table 120. Varicella Attenuated Live Vaccine Market Drivers
Table 121. Varicella Attenuated Live Vaccine Market Challenges
Table 122. Varicella Attenuated Live Vaccine Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Varicella Attenuated Live Vaccine
Figure 2. Global Varicella Attenuated Live Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Varicella Attenuated Live Vaccine Market Share by Type in 2023 & 2030
Figure 4. Monovalent Vaccine Product Picture
Figure 5. Combination Vaccine Product Picture
Figure 6. Global Varicella Attenuated Live Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Varicella Attenuated Live Vaccine Market Share by Application in 2023 & 2030
Figure 8. Kids Injection
Figure 9. Adults Injection
Figure 10. Global Varicella Attenuated Live Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Varicella Attenuated Live Vaccine Market Size (2019-2030) & (US$ Million)
Figure 12. Global Varicella Attenuated Live Vaccine Sales (2019-2030) & (K Doses)
Figure 13. Global Varicella Attenuated Live Vaccine Average Price (USD/Dose) & (2019-2030)
Figure 14. Varicella Attenuated Live Vaccine Report Years Considered
Figure 15. Varicella Attenuated Live Vaccine Sales Share by Manufacturers in 2023
Figure 16. Global Varicella Attenuated Live Vaccine Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Varicella Attenuated Live Vaccine Players: Market Share by Revenue in 2023
Figure 18. Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Varicella Attenuated Live Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Varicella Attenuated Live Vaccine Sales Market Share by Country (2019-2030)
Figure 21. North America Varicella Attenuated Live Vaccine Revenue Market Share by Country (2019-2030)
Figure 22. U.S. Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Varicella Attenuated Live Vaccine Sales Market Share by Country (2019-2030)
Figure 25. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Country (2019-2030)
Figure 26. Germany Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Varicella Attenuated Live Vaccine Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Varicella Attenuated Live Vaccine Revenue Market Share by Region (2019-2030)
Figure 33. China Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Taiwan Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Philippines Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Varicella Attenuated Live Vaccine Sales Market Share by Country (2019-2030)
Figure 44. Latin America Varicella Attenuated Live Vaccine Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Varicella Attenuated Live Vaccine Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. U.A.E Varicella Attenuated Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Varicella Attenuated Live Vaccine by Type (2019-2030)
Figure 54. Global Revenue Market Share of Varicella Attenuated Live Vaccine by Type (2019-2030)
Figure 55. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Type (2019-2030)
Figure 56. Global Sales Market Share of Varicella Attenuated Live Vaccine by Application (2019-2030)
Figure 57. Global Revenue Market Share of Varicella Attenuated Live Vaccine by Application (2019-2030)
Figure 58. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Application (2019-2030)
Figure 59. Varicella Attenuated Live Vaccine Value Chain
Figure 60. Varicella Attenuated Live Vaccine Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
  • Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 87
    The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......
  • Global Esomeprazole Magnesium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74
    The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030. North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......
  • Global Combination Therapy Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......
  • Global Axitinib Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 68
    The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......
  • Global Lyme Disease Vaccine Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 70
    The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi. The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at......
  • Global Transdermal Absorption Patch Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......
  • Global Ketoprofen Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......
  • Global Methyl Salicylate Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 82
    The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......
  • Global Diclofenac Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs